drugset

drugset / Trial / NCT04204616

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04204616 ↗

Phase 3 Active not recruiting 500 enrolled Galderma R&D

NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

Timeline

Start: 2021-01-11
Primary completion: 2026-10-26
Completion: 2026-10-26

Publications

Legat FJ, Kwatra SG, Reich A, Boulinguez S, Tsianakas A, Sauder M, Barbarot S, Szepietowski JC, Conrad C, Pink AE, Weisshaar E, Misery L, Metz M, Laquer VT, Sivamani RK, Yosipovitch G, Thaci D, Skov L, Chen X, Noda A, Jabbar-Lopez ZK, Piketty C, Stander S. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. J Eur Acad Dermatol Venereol. 2026 Jul;40(7):1195-1207. doi: 10.1111/jdv.70266. Epub 2025 Dec 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nemolizumab	Monoclonal antibody	30 mg	Subcutaneous
Subject	Nemolizumab	Monoclonal antibody	60 mg	Subcutaneous

Indications